Table 1. Demographic and Baseline Clinical Characteristics of Patients.
| Characteristic | Patients, No. (%) | |||||
|---|---|---|---|---|---|---|
| Total cohort | Incident group total (n = 183) | |||||
| Total (N = 276) | <12 y (n = 69) | 12-18 y (n = 45) | >18-40 y (n = 103) | >40 y (n = 59) | ||
| Age at onset, y | ||||||
| Mean (SD) | 26.4 (17.6) | 6 (2.9) | 14.6 (1.9) | 30 (5.9) | 52.6 (8.2) | 28.2 (18.1) |
| Median (range) | 25 (1-72) | 6 (1-11) | 14 (12-18) | 29 (19-40) | 52 (41-72) | 28 (1-72) |
| Sex | ||||||
| Female | 166 (60.1) | 40 (58.0) | 26 (57.8) | 65 (63.1) | 35 (59.3) | 106 (57.9) |
| Male | 109 (39.6) | 29 (42.0) | 19 (42.2) | 38 (36.9) | 24 (40.7) | 77 (42.1) |
| Race | ||||||
| No. with data | 246 | 57 | 41 | 96 | 55 | 158 |
| Asian total | 28(11.4) | 12 (21.1) | 3 (7.9) | 7 (7.3) | 6 (10.9) | 18 (11.4) |
| South Asian | 24 (9.8) | 10 (17.5) | 3 (7.9) | 7 (7.3) | 4 (7.3) | 14 (8.9) |
| East Asian | 4 (1.6) | 2 (3.5) | 0 | 0 | 2 (3.6) | 4 (2.5) |
| Black | 8 (3.3) | 2 (3.5) | 0 | 2 (2.1) | 4 (7.3) | 8 (5.1) |
| White | 204 (79.7) | 43 (75.5) | 33 (86.8) | 84 (87.5) | 44 (80) | 131 (82.9) |
| Mixed race or other racea | 6 (2.4) | 0 | 2 (5.3) | 3 (3.1) | 1 (1.8) | 1 (0.6) |
| Disease duration, mo | ||||||
| Mean (SD) | 62.1 (78.8) | 81.9 (104.7) | 73.7 (76.3) | 58.6 (76.3) | 42.7 (47.9) | 33.1 (33.7) |
| Median (range) | 35.0 (1.2-540.0) | 44.0 (1.2-540.0) | 50.7 (2.3-398.5) | 33 (1.6-422.6) | 29.7 (3.3-256) | 24.4 (1.2-235.1) |
| Clinical attack at onset | ||||||
| No. with data | 275 | 69 | 45 | 102 | 59 | 183 |
| ON | 119 (43.3) | 20 (29.0) | 15 (33.3) | 53 (52.0) | 31 (52.5) | 76 (41.5) |
| Unilateral, No. | 52 | 7 | 6 | 28 | 11 | 31 |
| Bilateral, No. | 58 | 12 | 9 | 20 | 17 | 38 |
| Unidentified, No. | 9 | 1 | 0 | 5 | 3 | 6 |
| TM | 51 (18.5) | 2 (2.9) | 10 (22.2) | 29 (28.4) | 10 (16.9 | 37 (20.2) |
| STM, No. | 6 | 0 | 0 | 5 | 1 | 4 |
| LETM, No. | 39 | 1 | 10 | 21 | 7 | 31 |
| Unidentified length TM, No. | 6 | 1 | 0 | 3 | 2 | 2 |
| ON with TM | 24 (8.7) | 0 | 7 (15.6) | 10 (9.8) | 7 (11.9) | 18 (9.8) |
| ADEM, brain, or BS | 81 (29.5) | 47 (68.1) | 13 (28.9) | 10 (9.8) | 11 (18.6) | 52 (28.5) |
| Follow-on steroid after onset attack | ||||||
| No. with data | 230 | 47 | 38 | 90 | 55 | 135 |
| None | 79 (34.4) | 9 (19.2) | 15 (39.5) | 38 (42.2) | 17 (30.9) | 39 (25.2) |
| <2 mo | 39 (16.9) | 16 (34.0) | 8 (21.1) | 11 (12.2) | 4 (7.3) | 27 (17.4) |
| 2-6 mo | 54 (23.5) | 18 (38.3) | 11 (28.9) | 18 (20.0) | 7 (12.7) | 17 (23.9) |
| >6 mo | 58 (25.2) | 4 (8.5) | 4 (10.5) | 23 (25.6) | 27 (49.1) | 52 (33.5) |
| Disease course | ||||||
| Monophasic | 137 (49.6) | 32 (46.4) | 21 (45.1) | 48 (47.4) | 36 (61.0) | 137 (74.9) |
| Relapsing | 139 (50.4) | 37 (53.6) | 24 (54.9) | 55 (52.6) | 23 (39.0) | 46 (25.1) |
| Unmatched CSF oligoclonal band | ||||||
| No. tested | 165 | 32 | 33 | 64 | 36 | 96 |
| With outcome | 20 (12.1) | 7 (21.8) | 1 (3.0) | 7 (10.9) | 5 (13.8) | 15 (15.6) |
| Family history of other autoimmune diseases | ||||||
| No. with data | 205 | 60 | 32 | 66 | 47 | 139 |
| With outcome | 68 (33.2) | 8 (3.3) | 8 (25.0) | 33 (50.0) | 19 (40.4) | 43 (30.9) |
| Associated with other autoantibodies | ||||||
| No. with data | 268 | 68 | 43 | 101 | 56 | 176 |
| With outcome | 32 (11.9) | 7 (10.3) | 10.2 (49.0 | 14 (13.9) | 6 (10.7) | 20 (11.4) |
| ARR, mean (SD)b | 0.59 (0.50 | 0.56 (0.60) | 0.57 (0.38) | 0.62 (0.46) | 0.60 (0.53) | 0.58 (0.49) |
Abbreviations: ADEM, acute disseminated encephalomyelitis; ARR, annual relapse rate; BS, brain stem; CSF, cerebrospinal fluid; LETM, long extensive transverse myelitis; ON, optic neuritis; STM, short transverse myelitis; TM, transverse myelitis.
a
Individuals with mixed race and other race were those who self-identified as others outside of the categories listed in this table. Mixed race and other race were combined owing to low numbers; mixed race was a specific term used in data collection.
b
For ARR, only individuals with disease duration of 12 months or more were included.